Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s shares closed last Friday at $397.27.

Oppenheimer downgraded Vertex ... source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on VRTX: Vertex Pharmaceuticals ...

Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...

Vertex Pharmaceuticals has received FDA approval for Alyftrek in cystic fibroris, six years and older. The approval increases the company’s CF opportunity by around 6,000 patients at launch.

The announcement comes directly from Vertex Pharmaceuticals (NASDAQ ... threatening condition that affects the lungs and digestive system. This approval will allow many of the patients with ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

In addition, please check the fund’s top five holdings to know its best picks in 2024. Hardman Johnston Global Equity highlighted stocks like Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), in the ...

Bernstein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $441 from $506 and keeps a Market Perform rating on the shares. The firm thinks suzetrigine is at least somewhat ...